Compare Abeona Therapeutics Inc (ABEO) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dropbox Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Dropbox Inc trades at $29.01 (market cap $6.73B). The key difference: Dropbox Inc is far larger — about 18× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | DBX | |
|---|---|---|
Market Cap | $373.32M | $6.73B |
Sector | Health | Technology |
52-Week High | $7.23 | $32.17 |
52-Week Low | $4.17 | $22.06 |
Enterprise Value | $228.22M | $9.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DBX trades at $28.85, up 1.02% today, with a bullish technical signal from moving averages and a consensus price target of $30.00. The company maintains strong profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent developments include a new $900 million stock repurchase program and CEO transition news from Reuters on 2026-05-26.
Outlook remains positive with steady revenue near $2.5 billion and robust cash flow, though risks include high debt levels and competitive pressures. The stock offers moderate upside to the price target with support from buybacks, but investors should monitor execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
